TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05404932
Drug: Aliquoted allogeneic donor plasma in patient's conjunctiva
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 drops of allogenic aliquoted plasma to affected eye every 1-5 hours per day based on disease severity to be weaned down based on clinical response Administration period: Two to Six months. This may be repeated based on recurrence/worsening of conjunctivitis
Study: NCT06518018
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group receives the current standard of care for second-line treatment of advanced NSCLC. This regimen consists of a combination of immunotherapy and chemotherapy , both administered intravenously
Study: NCT05448469
Drug: conventional analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive combined general anesthesia and conventional analgesia
Study: NCT05861713
Drug: Hydrating Cream
Normalized name: CeraVe Hydrating Cream to Foam Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group will apply the Hydrating Cream to the affected skin area at least twice daily with a cotton swab, while the other limb was the control group.
Study: NCT06122311
Drug: N Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine sachets 600 mg twice daily
Study: NCT05359861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by IV
Study: NCT06565845
Drug: triple anti-tuberculosis drug
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients took oral rifampin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).
Study: NCT04916236
Drug: RMC-4630
Approvals — FDA: no, EMA: no, PMDA: no
Description: * SHP2-inhibitor~* Powder in capsule~* Administered on day 1 and day 2 of every week
Study: NCT04783090
Drug: MT1013
Approvals — FDA: no, EMA: no, PMDA: no
Description: bispecific peptide as a CaSR agonist and a functional OGP analogue
Study: NCT04916236
Drug: LY3214996
Approvals — FDA: no, EMA: no, PMDA: no
Description: * ERK inhibitor~* Powder in capsule~* Administered every day
Study: NCT05245292
Drug: 3BNC117-LS
Normalized name: Emcor LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 3BNC117-LS at 30 mg/kg
Study: NCT05613062
Drug: Modified Huang-Lian-Jie-Du Decoction (MHLJDD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine granules for 12 weeks twice daily
Study: NCT05613062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granules for 12 weeks twice daily
Study: NCT05298449
Drug: HU-045
Approvals — FDA: no, EMA: no, PMDA: no
Description: HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder
Study: NCT05298449
Drug: Xeomin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.
Study: NCT05025956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 8 days total.
Study: NCT06168084
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
Study: NCT05716516
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer
Study: NCT05317741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received matching placebo tablet orally on Day 1.
Study: NCT06516419
Drug: Concentrated secretome Injection 2mL
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by IPT RSCM Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.
Study: NCT06516419
Drug: Triple Combination Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream (Refaquin) containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle.
Study: NCT04993157
Drug: FIA586
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIA586 capsule
Study: NCT00463723
Drug: FK506 0.06% (eye drops)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05293041
Drug: Argipressin
Normalized name: argipressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of Argipressin 0.8 U/ml, 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the treatment arm.
Study: NCT06522542
Drug: systematic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
Study: NCT06340932
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg BID
Study: NCT06340932
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg q8h
Study: NCT06340932
Drug: Acetaminophen 500Mg Cap
Normalized name: ACETAMINOPHEN 500MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg q6h prn
Study: NCT05672836
Drug: Standard-of-Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-Care medical therapy plus Enavogliflozin matching placebo
Study: NCT05746806
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In combination to the radiotherapy a short term androgen deprivation drug for 6 months will be applied.~The drug concept used is:~- LHRH(Luteinizing hormone releasing hormone)-agonist with 3-month subcutaneous depot injection (e.g. Pamorelin® LA (Triptorelin) 11.25mg s.c.) in combination with nonsteroidal antiandrogen (e.g. Bicalutamide 50mg/day) as flare protection at least 5 days before and max. 15 days after first LHRH-injection
Study: NCT05521984
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care
Study: NCT05029141
Drug: CAHAG regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial.
Study: NCT05029141
Drug: Placebo regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chidamide 0mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial.
Study: NCT05408546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05216744
Drug: Ceftriaxone 1000mg + doxycycline 100 mg
Normalized name: ceftriaxone 1000 MG
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
Study: NCT05216744
Drug: Cefixime 800mg + doxycycline 100 mg
Normalized name: (-)-cefixim
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
Study: NCT05989828
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05595369
Drug: Experimental: Paxlovid 25 day dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Paxlovid 25 day dosing Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days See NCT05965726 (Paxlovid Sub-study)
Study: NCT05595369
Drug: Experimental: Paxlovid 15 day dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Paxlovid 15 day Dosing Paxlovid (nirmatrelvir 300mg and ritonavir 100mg) bid x 15 days then ritonavir 100mg bid plus nirmatrelvir matching placebo bid x 10 days See NCT05965726 (Paxlovid Sub-study)
Study: NCT05595369
Drug: Placebo Comparator: Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Control ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid bid x 25 days See NCT05965726 (Paxlovid Sub-study)
Study: NCT05724511
Drug: MIYAIRI 588
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the 3 months intervention, each subjects take 1g/package with meal, and 3 packages/day.
Study: NCT04849559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsule
Study: NCT04776655
Drug: Calcium levofolinate
Normalized name: calcium levofolinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
Study: NCT05613465
Drug: Codonopsis
Normalized name: CODONOPSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codonopsis pilosula Nnannf is oral liquid, which has been approved for listing
Study: NCT05613465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is packaged in the same package as the drug
Study: NCT05696093
Drug: standard antibiotic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of standard antibiotic therapy for enterobacterial VAP
Study: NCT04431960
Drug: blackcurrant (BC) extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
Study: NCT04994002
Drug: CERC-006
Normalized name: CERCIS SILIQUASTRUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT05415917
Drug: Gemcitabine and Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A chemotherapy cycle will constitute 28 days of treatment:~1. Gemcitabine: 1000 mg/m2 IV on days 1, 8, and 15 of each 28-day cycle~2. Capecitabine: 1660 mg/m2 per day orally on days 1 through 21 of each 28-day cycle.
Study: NCT06650371
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: opioid based anesthesia analgesia will be offered by fentanyl in induction and maintenance according to Ideal Body Weight (IBW).
Study: NCT05593562
Drug: SPH3127
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 100 mg \[14 c\] SPH3127 mixed suspension
Study: NCT06329895
Drug: BAY2927088
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT06329895
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration.
Study: NCT05385783
Drug: CYB003
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYB003 is a synthetic psilocybin analog.
Study: NCT05385783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04822701
Drug: Placebo intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous
Study: NCT04822701
Drug: Placebo inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaled
Study: NCT05121038
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~* Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~* Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~* Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home.
Study: NCT06537921
Drug: Minocycline 200mg
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage: 2x100mg/daily for 8 weeks
Study: NCT05651373
Drug: CertolizumabPegol injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.
Study: NCT06006416
Drug: Fenugreek Fibre
Normalized name: FENUGREEK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 2 x 10g per day with/in food
Study: NCT05543993
Drug: Bivalent COVID-19 Booster
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent COVID-19 Booster by Pfizer or Moderna
Study: NCT04800159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporization of placebo
Study: NCT06445517
Drug: ISM8207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical formulation: Capsules Mode of Administration: Oral
Study: NCT05688124
Drug: IBI351
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI351 is administered orally
Study: NCT05867771
Drug: PM1022
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM1022 Injection
Study: NCT05436743
Drug: K-Y Jelly, Topical Gel soaked packs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel used as lubricant
Study: NCT05200234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo+ standard treatment
Study: NCT05844995
Drug: Acetaminophen/Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
Study: NCT05560230
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation
Study: NCT04815148
Drug: MH004 Ib-1(0.1%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
Study: NCT04815148
Drug: MH004 Ib-1(0.3%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
Study: NCT04815148
Drug: MH004 Ib-1(1%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
Study: NCT04815148
Drug: MH004 Ib-2(0.3%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
Study: NCT04815148
Drug: MH004 Ib-2(1%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
Study: NCT04815148
Drug: MH004 Ib-2(3%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
Study: NCT06327295
Drug: ATB1651-102- Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 20 weeks with a follow-up for 16 weeks.
Study: NCT06327295
Drug: ATB1651-102- Cohort 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form- Topical solution; Dosage- 5% formulation The participants will apply the daily dose of 5% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
Study: NCT06327295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will receive matching placebo across cohorts 1-4 of the study.
Study: NCT06520384
Drug: Alcohol 30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 30% alcohol in 0.25% bupivacaine.
Study: NCT06520384
Drug: Alcohol 50%
Normalized name: Isopropyl Alcohol 50% Topical application Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 50% alcohol in 0.25% bupivacaine.
Study: NCT06520384
Drug: Alcohol 70%
Normalized name: Alcohol 70% Prep Pads (Medium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 70% alcohol in 0.25% bupivacaine.
Study: NCT00002317
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06525766
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05856136
Drug: Fentanyl Injection
Normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Three different fentanyl doses (used for sedation) will be evaluated on their effects on shear wave elastography (SWE) and breathing
Study: NCT04793022
Drug: Inhaled Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia given with inhaled anesthetics
Study: NCT06163508
Drug: Q-Cells®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term observational study of patients who received 1 of 3 different amounts of Q-Cells®.
Study: NCT05744804
Drug: -group of patients(75 patients) will receive low dose rivaroxaban myocardial infarction plus (acetylsalicylic acid 75 mg and clopidogrel 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive low dose rivaroxaban (rivaroxaban 2.5 mg twice daily orally) for 1 month after anterior ST-segment myocardial infarction plus dual antiplatelet therapy (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally)
Study: NCT05744804
Drug: (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally only)
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group of patients: 75 Patients of anterior ST-segment myocardial infarction on dual antiplatelet therapy only
Study: NCT06504290
Drug: VV119 Placebo （in healthy adult subjects）
Approvals — FDA: no, EMA: no, PMDA: no
Description: VV119 0.5 mg Group:2 subjects will receive VV119 Placebo 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:2 subjects will receive VV119 Placebo 1 mg, orally once daily for 14 days.~VV119 2 mg Group:2 subjects will receive VV119 Placebo 2 mg, orally once daily for 14 days.~VV119 4 mg Group:2 subjects will receive VV119 Placebo 4 mg, orally once daily for 14 days.
Study: NCT06504290
Drug: VV119 （in healthy adult subjects）
Approvals — FDA: no, EMA: no, PMDA: no
Description: VV119 0.5 mg Group:6 subjects will receive VV119 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:6 subjects will receive VV119 1 mg, orally once daily for 14 days.~VV119 2 mg Group:6 subjects will receive VV119 2 mg, orally once daily for 14 days.~VV119 4 mg Group:6 subjects will receive VV119 4 mg, orally once daily for 14 days.
Study: NCT06504290
Drug: VV119(in adult patients with schizophrenia)
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VV119 2 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, then take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the seventh day , then 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily.
Study: NCT05504642
Drug: Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab)
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: In week 1-7, standard administration of concurrent Cisplatin mono 40mg/m2 body surface area d1, 8, 15, 22, 29 (Monday of each treatment week) during radiotherapy. Simultaneous application of Nivolumab 3mg/kg week 1, 3, 5, 7 (on Thursday) and Ipilimumab 1mg/kg in week 5 (on Thursday).